{"id":"rocuronium-or-vecuronium","safety":{"commonSideEffects":[{"rate":null,"effect":"Prolonged neuromuscular blockade"},{"rate":null,"effect":"Histamine release (rocuronium more than vecuronium)"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Bronchospasm"}]},"_chembl":{"chemblId":"CHEMBL1200629","moleculeType":"Small molecule","molecularWeight":"637.74"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These drugs are non-depolarizing (competitive) neuromuscular blockers that antagonize acetylcholine at the motor endplate by occupying nicotinic acetylcholine receptors without activating them. This prevents acetylcholine from binding and initiating muscle contraction, resulting in paralysis. They are used during anesthesia to facilitate intubation and maintain muscle relaxation during surgery.","oneSentence":"Rocuronium and vecuronium are neuromuscular blocking agents that competitively bind to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:33.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Facilitation of endotracheal intubation during anesthesia induction"},{"name":"Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation"}]},"trialDetails":[{"nctId":"NCT05792436","phase":"NA","title":"Continuous Versus 1-min Oscillometric Arterial BP Monitoring","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2023-04-27","conditions":"Anesthesia, General","enrollment":258},{"nctId":"NCT07239141","phase":"NA","title":"Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective Surgery","status":"RECRUITING","sponsor":"Mario Zamudio","startDate":"2025-12-04","conditions":"Airway Management, Intubation, Endotracheal","enrollment":252},{"nctId":"NCT03263117","phase":"PHASE4","title":"SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2018-07-01","conditions":"Stroke","enrollment":260},{"nctId":"NCT03909165","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-07-23","conditions":"Neuromuscular Blockade","enrollment":145},{"nctId":"NCT05246397","phase":"PHASE4","title":"Sugammadex Titration in Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Washington","startDate":"2022-02-01","conditions":"Coronary Artery Disease, Valvular Heart Disease, Aorta Disease","enrollment":100},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT05468671","phase":"PHASE4","title":"Clinical Application Value of Remazolam Combined With Sugammadex Sodium in Anesthesia for Endotracheal Surgery Under Bronchoscopy","status":"COMPLETED","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-01-04","conditions":"Endobronchial Metastases, Bronchoesophageal Fistula, General Anesthetic Drug Adverse Reaction","enrollment":34},{"nctId":"NCT01422304","phase":"PHASE3","title":"Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-10-12","conditions":"Neuromuscular Blockade, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee","enrollment":1198},{"nctId":"NCT03351608","phase":"PHASE4","title":"Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-12","conditions":"Neuromuscular Blockade","enrollment":288},{"nctId":"NCT03346070","phase":"PHASE4","title":"Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-01-01","conditions":"Neuromuscular Blockade","enrollment":207},{"nctId":"NCT03540030","phase":"PHASE4","title":"Opioid-Free Shoulder Arthroplasty","status":"COMPLETED","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2016-09","conditions":"Opioid Use, Shoulder Osteoarthritis, Avascular Necrosis","enrollment":86},{"nctId":"NCT03346057","phase":"PHASE4","title":"Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-12-20","conditions":"Reversal of Neuromuscular Blockade","enrollment":344},{"nctId":"NCT00552617","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09-20","conditions":"Anesthesia, General","enrollment":100},{"nctId":"NCT00473694","phase":"PHASE3","title":"Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-11-28","conditions":"Anesthesia, General","enrollment":182},{"nctId":"NCT00591786","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-12-05","conditions":"Anesthesia, General","enrollment":100},{"nctId":"NCT00552929","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10-04","conditions":"Anesthesia, General","enrollment":102},{"nctId":"NCT00451217","phase":"PHASE3","title":"Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-11-17","conditions":"Anesthesia, General","enrollment":198},{"nctId":"NCT00591409","phase":"PHASE2","title":"A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-01-03","conditions":"Anesthesia, General","enrollment":100},{"nctId":"NCT02237443","phase":"PHASE4","title":"Mask Ventilation Before and After Neuromuscular Blockade","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-08","conditions":"Anesthesia","enrollment":210},{"nctId":"NCT02134093","phase":"PHASE4","title":"Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients","status":"UNKNOWN","sponsor":"Tang-Du Hospital","startDate":"2014-07","conditions":"Postoperative Confusion","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7061,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rocuronium or Vecuronium","genericName":"Rocuronium or Vecuronium","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rocuronium and vecuronium are neuromuscular blocking agents that competitively bind to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction. Used for Facilitation of endotracheal intubation during anesthesia induction, Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}